



Special points of interest for Primary Care

- ENT Infection Management
- BBV Exposure

SMC advice:

- Azelastine / fluticasone (Dymista® nasal spray)
- Botulinum toxin type A (Botox®)
- Cefuroxime sodium (Aprokam®)
- Cobicistat (Tybost®)
- Eltrombopag (Revolade®)
- Imiquimod (Zyclara®)
- Mannitol (Bronchitol®)
- Micronized progesterone (Utrogestan Vaginal®)
- Saxagliptin (Onglyza®)
- Vemurafenib (Zelboraf®)
- Vildagliptin (Galvus®)



Specialist lists - progress

Work has been done on the Epilepsy specialist formulary list. This is due to be discussed at the February Medicines Advisory Group (MAG) meeting.



Guidelines and Protocols

Antimicrobial guidance update

All the guidance detailed below can be viewed on the [Antibiotic Website](#) at section 5 of the NHS [Tayside Area Formulary](#).

Updated guidance

- Linezolid is a restricted '[Alert Antibiotic](#)' which can only be prescribed with prior authorisation from ID or Microbiology and completion of a Mandatory Order Form. This document and the guidance on toxicities, monitoring, duration of treatment and interactions are available on the [NHS Tayside Guide to Antibiotic Use](#) (Antibiotic Website).
- Guidance on the choice of antimicrobials for hospital acquired pneumonia or aspiration pneumonia for patients with penicillin allergy has been added to the Antibiotic Website.
- Other guidance which has been reviewed and updated:
 - hospital treatment of cellulitis
 - MRSA treatment

New guidance

- A new local guideline has been added to the Antibiotic Website: [ENT Infection Management](#). This guidance is aimed at prescribers working in both primary and secondary care.
- **BBV Exposure**
- NHS Tayside has approved new guidance for the management of blood borne virus (BBV) exposure events in the community. This guidance is aimed at all NHS Tayside staff, including Primary Care, Minor Injuries Units, Sexual Health Clinics and the Emergency Department, where people may present who have been put at risk of transmission of BBV (there is separate guidance for NHS Tayside workers who sustain a contamination/needlestick injury on Staffnet).
- The guidance can be found via Knowledge Finder in Clinical Portal (enter BBV and Clinical Pathways & Information) or visit <http://www.bbvmcntayside.scot.nhs.uk/BBV%20Guidelines.html>
- The community and NHS staff documents can both also be found on the Antibiotic Website in the HIV and BBV section.
- 2 new national guidelines have also been added to the Antibiotic Website:
 - [Decision aid for diagnosis and management of suspected UTI in older people](#)
 - [Good Practice Recommendations for Antimicrobial Use in the Frail Elderly](#)

Inside this issue :

Specialist lists - progress	1
Guidelines & Protocols	1
Drug Safety Updates	1
SMC Advice issued in December 2013	2-3
Updates from previous SMC Advice	3
TAF Updates	4
SMC Briefing Note	4
Forthcoming SMC Advice	4



Drug Safety Updates

Please follow link - January 2014 not yet available

Medicine	Indication	Local recommendation category	Comments and useful links
Azelastine hydrochloride 137micrograms plus fluticasone propionate 50micrograms per actuation nasal spray (Dymista® nasal spray) (921/13) - <i>Abbreviated submission</i>	For the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intra-nasal antihistamine or glucocorticoid is not considered sufficient.	Not recommended	SMC advice
Botulinum toxin type A 50, 100, 200 Allergan units (Botox®) (931/13) - <i>Non-submission</i>	Management of bladder dysfunctions in adult patients with overactive bladder with symptoms of urinary incontinence, urgency and frequency who are not adequately managed with anticholinergics.	Not recommended	SMC advice
Cefuroxime sodium (Aprokam®) 50 mg powder for solution for injection (932/13) - <i>Non-submission</i>	Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.	Not recommended	SMC advice
Eltrombopag, 25mg, 50mg, 75mg film-coated tablets (Revolade®) (919/13) - <i>Full submission</i>	In adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.	Hospital Only - Hepatitis C Clinic Gastroenterology Specialist List Supplied via a Patient Access Scheme	SMC advice SPC link
Imiquimod (Zyclara®) 3.75% cream (934/13) - <i>Non-submission</i>	Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.	Not recommended	SMC advice
Mannitol 40mg inhalation powder hard capsule (Bronchitol®) (837/13) - <i>Resubmission</i>	Treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. SMC restriction: As an add-on to best standard of care in adult patients with CF who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and have rapidly declining lung function and in whom other osmotic agents are considered unsuitable.	*Pending Specialist feedback	SMC advice SPC link
Micronized progesterone (Utrogestan Vaginal®) 200 mg capsules (935/13) - <i>Non-submission</i>	Supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.	Not recommended	SMC advice
Saxagliptin 2.5mg and 5mg film-coated tablets (Onglyza®) (918/13) - <i>Full submission</i>	In adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. SMC restriction: as an alternative dipeptidyl peptidase-4 inhibitor option.	Formulary 1st choice Gliptin	SMC advice SPC link
Vemurafenib 240mg film-coated tablet (Zelboraf®) (792/12) - <i>Resubmission</i>	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. SMC restriction: for use in the first-line treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma.	Hospital Only Oncology Supplied via a Patient Access Scheme	SMC advice SPC link

Medicine	Indication	Local recommendation category	Comments and useful links
Vildagliptin 50mg tablets (Galvus®) (875/13) - Full submission	Treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. SMC restriction: as an alternative dipeptidyl peptidase-4 inhibitor option.	Non-formulary	SMC advice SPC link

'Local processes exist to allow consideration of prescribing outwith SMC advice or outwith NHS Tayside formulary. Details are available in the [NHS Tayside Policy on the Prescribing of Medicines that are Non-formulary \(including Individual Patient Treatment Requests\)](#)'

* 'pending' means that no local recommendation to support use is in place at the current time

'Local processes exist to allow consideration of prescribing outwith SMC advice or outwith NHS Tayside formulary. Details are available in the [NHS Tayside Policy on the Prescribing of Medicines that are Non-formulary \(including Individual Patient Treatment Requests\)](#)'

Tayside Area Formulary (TAF) Updates - Dec 13/Jan 14

TAF Section	Drug(s)/topic	Changes
Specialist formulary lists and formulary development	Gastroenterology	Eltrombopag (Revolade®) added to Gastroenterology specialist list.
2.5 & netFormulary * Obstetrics & Gynaecology specialist list	Centrally acting antihypertensive drugs	Methyldopa added to formulary and Obstetrics & Gynaecology specialist formulary list as Hospital Only for pregnancy induced hypertension (3rd line), restricted to the Cardiovascular Risk and Obstetrics clinics. Moxonidine added to formulary as Hospital Only for severe resistant hypertension restricted to the Cardiovascular Risk clinic.
2.6 & netFormulary *	Dihydropyridine calcium-channel blockers	Lercanidipine hydrochloride added to formulary for hypertension in patients intolerant of amlodipine.
4.2.1 Mental Health specialist list	Antipsychotic drugs	Link to NHS Tayside Guidelines for Management of High Dose Antipsychotic Therapy added to formulary and Mental Health specialist formulary list.
4.6 & netFormulary *	Metoclopramide	Updated advice on restricted dose and duration of use for metoclopramide (maximum dose in 24 hours: 30mg or 0.5mg/kg and short-term use (up to 5 days)) added. Link to MHRA Drug Safety Update, August 2013 with advice following European review confirming risk of neurological adverse effects.
6.1 & netFormulary *	Gliptins (DPP-4 inhibitors)	Saxagliptin now first choice gliptin. Triple oral therapy indication added as per SMC advice (see page 2 of this supplement). Sitagliptin may still be preferred in some patients - see formulary for further information on indications.
6.6 Endocrinology specialist list Medicine for the Elderly specialist list	Drugs affecting bone metabolism	Link to the Tayside MFE Osteoporosis Treatment Algorithm , September 2013 added outlining treatment options for osteoporosis and their place in therapy.

* Tayside netFormulary currently under development and not available for open access.

SMC Briefing Note:
[Click here](#) for December Briefing Note

[Forthcoming SMC Advice](#)

This bulletin is produced by the Medicines Advisory Group (MAG), which is a sub-group of the NHS Tayside Drug and Therapeutics Committee.

Please direct any queries to either:

Karen Harkness
Principal Pharmacist - Clinical Effectiveness
email: kharkness@nhs.net

or

Claire James
Senior Pharmacist - Clinical Effectiveness
email: clairejames@nhs.net

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use.

[CLICK HERE](#) for access to the Medicines Governance section of the Pharmacy Staffnet site.